Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph phase_3
3
60%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Terminated(1)

Detailed Status

Not yet recruiting2
Withdrawn1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

withdrawn120%
active_not_recruiting120%
recruiting120%
not_yet_recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
not_yet_recruitingphase_3

A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration

NCT07489586
not_yet_recruiting

Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration

NCT07423429
recruitingphase_3

Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

NCT07389980
active_not_recruitingphase_3

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

NCT06491914
withdrawn

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

NCT06398080

Clinical Trials (5)

Showing 5 of 5 trials
NCT07489586Phase 3

A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration

Not Yet Recruiting
NCT07423429

Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration

Not Yet Recruiting
NCT07389980Phase 3

Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

Recruiting
NCT06491914Phase 3

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Active Not Recruiting
NCT06398080

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5